Overview A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene Status: Recruiting Trial end date: 2025-12-31 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC. Phase: Phase 2 Details Lead Sponsor: AnHeart Therapeutics Inc.